Introduction
There are twelve essential fatty acids (EFAs) that are subdivided into two structural categories depending on the saturation state of the molecule. The designation omega-3 (ω-3) or omega-6 (ω-6), respectively, indicates if the third or sixth carbon from the methyl terminus is unsaturated.
The ω-3 and ω-6 fatty acids are derived from the dietary intake of the 18-carbon precursors α-linolenic acid and linoleic acid, respectively. The ω-3 fatty acids include: alpha-linolenic acid Dietary provision of long chain ω-3 and ω-6 fatty acids is essential because mammals are incapable of synthesizing fatty acids with a double bond past the delta-9 position, thus, dietary intake of EFAs has far-reaching consequences on membrane composition in all cells in the body and may influence neural function as well. The elucidation of the role for EFAs in neuronal function has followed two disparate lines of investigation. One approach has focused on the effects of dietary intake of EFAs on neuronal membrane composition and function. The reduction of dietary ω-3 fatty acids has been shown to have deleterious effects on cAMPdependent protein kinase A (PKA) and protein kinase C (PKC) activities (1,2), brain membrane lipid composition (3), neurotransmission (4, 5) , and learning ability in rats (6) . In addition, increasing dietary intake of ω-3 fatty acids can improve learning and memory tasks in young rats and overcome deficits in long-term potentiation (LTP) (7), a robust form of synaptic plasticity, in aged rats. These effects are theorized as being due to physical alterations in membrane characteristics, changing either the fluidity or rigidity of the membrane itself, and affecting neurotransmitter release as well as receptor and channel function (8) (9) (10) ).
An alternative investigative approach has focused on the effect in vitro of direct application of ω-3 fatty acids on cellular biochemistry and synaptic transmission. Early reports showed that a variety of fatty acids are capable of activating PKC (11) (12) (13) ; however, in other studies ω-3 and ω-6 fatty acids caused inhibition when PKC was activated with phosphatidyl serine (PS) and diacylglycerol (DAG) (14) . This latter effect may explain more recent reports that the application of ω-3 fatty acids to hippocampal slices can decrease membrane excitability and block low by guest on http://www.jbc.org/
Downloaded from
Protein Kinase inhibition by Omega-3 Fatty Acids 4 frequency stimulation-induced long-term depression (LTD) (15) (16) (17) . Overall these reports suggest a multi-faceted role for ω-3 EFAs involving both direct and indirect actions on neural function, and suggest the hypothesis that ω-3 fatty acids may affect protein kinase activity.
Questions concerning the mechanisms of action of EFAs are not trivial, as EFAs have been shown to have profound behavioral effects in humans in vivo. For example, dietary EPA and DHA elicit beneficial effects in certain neuropsychiatric disorders, such as Bipolar Disorder and schizophrenia. New studies of patients with manic-depression have shown significant reduction in reoccurrence of symptoms when the standard lithium treatment is supplemented with ω-3 fatty acids (18) . The exact cellular and biochemical mechanisms underlying the mood-stabilizing effect of ω-3 fatty acids are mysterious, making this a necessary and attractive area for study.
To better understand the biochemical affects of ω-3 fatty acids on the CNS, we focused our attention on their effects on the activities of prevalent protein kinases of the CNS, using kinase assays in vitro. We found that DHA and EPA reduced the activity of protein kinase C, cAMPdependent protein kinase A, mitogen activated protein kinase (MAPK) (ERK1 and ERK2), and Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) at low concentrations (IC 50 2-36 µM).
These effects appear to be dependent on the ω-3 double bond within the fatty acid, as structurally similar compounds saturated at the ω-3 position had little or no effect on kinase activity. We also used the hippocampal slice preparation to assess whether ω-3 fatty acids were capable of affecting protein kinase activity in the living neuron. In one series of studies, we observed that DHA and EPA inhibited serotonin (5-HT) receptor-induced activation of MAPK. In another study, we capitalized on the fact that hippocampal long-term potentiation (LTP) is known to require protein kinase activation. We observed that perfusion of DHA or EPA onto hippocampal slices interfered with the induction of LTP in area CA1, presumably through the reduced activity of multiple protein kinases and disruption of the signaling pathways in which they are involved.
Thus, the ω-3 fatty acids are surprisingly potent and efficacious broad-spectrum protein kinase inhibitors, suggesting that protein kinases may be a target of action for ω-3 fatty acids in vivo. 
Protein Kinase assays:
PKC assay-Enzyme activity was measured by quantifying incorporation of PKA Assay-Assays for PKA activity were performed as described in Roberson and Sweatt (1996) with the exception that PKC and CaMKII inhibitors were absent from the reaction buffer and the chromatography papers were washed in 75 mM H 3 PO 4 3 x 10 minutes before rinsing in methanol. Kemptide (100 µM) was used as the substrate for PKA.
CaMKII Assay -The assays were performed as described in Roberson and Sweatt (1996) .
Reaction conditions consisted of 20 mM Tris-HCl, 10 mM MgCl 2 , 0.5 mM DTT, 0.1 mM Na 2 -EDTA, 100 µM autocamtide, 25 units CaMKII, 2.4 µM Calmodulin and 2 mM CaCl 2 (to activate the enzyme), 100 µM ATP and gamma-labeled ATP to a final specific activity of 100 µCi/µmol. The mixture was incubated for 10 minutes at 30°C before stop solution was added. (stop solution). Two aliquots of each sample were transferred onto P-51 chromatography paper.
After 2 minutes of incubation at room temperature the filter papers were washed 4 x 3 minutes in 100 ml of 75 mM H 3 PO 4 and then briefly in 95% (v/v) ethanol with gentle agitation.
Chromatography papers were air dried before the γ- Hippocampal MAPK activation and quantitation -Hippocampal slices (400 µm) were prepared from 8-12 week-old, male mice as described previously (19) . Slices were allowed to recover in artificial cerebral spinal fluid (ACSF)(125 mM NaCl, 2.5 mM KCl, 1.24 mM NaH 2 PO 4 , 25 mM NaHCO 3 , 10 mM D-glucose, 2 mM CaCl 2 and 1 mM MgCl 2 ) for 3 hours at 32 o C. Omega-3 fatty acids or control fatty acids (10 µM) were added to slices for one hour prior to 5-HT addition. 5-HT was added to slices at a 10 µM concentration for 10 min. at which time the slices were collected and frozen on dry ice. Slices were then homogenized and samples were prepared as described previously (19) . Each n represents the pooled protein homogenate from three whole hippocampal slices. The samples were electrophoresed on 10% SDS-polyacrylamide gels, and by guest on http://www.jbc.org/
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Protein Kinase inhibition by Omega-3 Fatty Acids 7 transferred to Immobilon-P membranes. Membranes were blocked in 5% dry milk solution and 1 µM microcysteine for 1 hour. All blots were incubated at room temperature and washed in TTBS buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween 20).
Immunoreactivity was assessed using the enhanced chemiluminescence method (Amersham Pharmacia Biotech, Arlington Heights, IL). The bands corresponding to phospho-p42 MAPK on each western blot were quantified to densitometry using a StudioScan desktop scanner and NIH Image software.
Hippocampal slice physiology -Hippocampal slices (400 µm) were prepared from 8-12 weekold, male mice as described previously (19) . Slices were perfused (1ml/min.) with ACSF in an interface chamber maintained at 25 o C. Field recordings of the Schaffer collateral synapse were monitored for a minimum of 10 minutes before fatty acid application to insure a stable baseline.
Responses are presented as an average of 6 individual traces. Baseline stimulus intensities were determined from the intensity that produced a field EPSP at 50% of the maximal response. LTP (Figure 1 ) lacking the ω-3 moiety were used as controls for DHA. BA, the saturated form of DHA, did not significantly inhibit PKA activity (Figure 2A) . DTEA, which not only lacks the ω-3 double bond but also lacks the double bond in the fourth position, had a substantially higher IC 50 than DHA, with an IC 50 of 230 µM. These results demonstrate that DHA is more potent in PKA inhibition than BA and DTEA, and suggest that the ω-3 double bond is important in conferring potency and efficacy for inhibition of PKA. As controls for EPA we evaluated arachidic acid and AA. Arachidic acid, the saturated form of EPA lacking the ω-3 double bond, was not potent in the inhibition of PKA phosphotransferase activity as EPA. This was evident in the calculated IC 50 of >400 µM for Arachidic acid. In addition, a calculated IC 50 of 59 µM for AA, which is structurally equivalent to EPA except for the lack of the ω-3 double bond, was 30-fold greater than the IC 50 for EPA of 2 µM ( Figure 2B ). Overall these data indicate that both DHA and EPA effectively inhibit PKA activity in vitro and suggest that the ω-3 double bond plays an important role in conferring inhibitory efficacy and potency for both types of compounds.
The ω-3 fatty acid moiety is important in inhibiting PKA activity Given the results described above, we wanted to test if the presence of the ω-3 double bond was sufficient to confer inhibitory efficacy. We therefore tested two other long-chain fatty acids that have the ω-3 double bond moiety incorporated into their structure. Toward this end we evaluated Cis11,14,17 Eicosatrienoic acid (ESEA), a twenty-carbon ω-3 fatty acid with three double bonds, and Cis 7,10,13,16,19 Docosapentaenoic acid (DPEA), a twenty-two carbon ω-3 fatty acid with a total of five double bonds ( Figure 1 ). We examined whether ESEA or DPEA exhibited inhibitory effects by evaluating the effect of increasing concentrations (1.0 µM to 400 µM for ESEA and 0.1 µM to 400 µM for DPEA) on PKA phosphotransferase activity ( Figure   2C ). We found that both ESEA and DPEA blocked PKA catalytic subunit activity; IC 50 s were calculated to be 22 µM for ESEA and 10 µM for DPEA. Once again these data suggest that the ω-3 double bond plays an important role in the inhibition of PKA by these long-chain fatty acids. This is illustrated quite nicely, for example by comparing the potencies of DTEA versus DPEA (Figure 2A and 2C ). These two compounds are structurally identical with the exception of the ω-3 double bond contained within DPEA, which showed much greater potency than DTEA in PKA inhibition.
EPA is not a competitive inhibitor of ATP.
Most broad-spectrum inhibitors of second-messenger regulated kinases are competitive with ATP (20,21), and we sought to determine if this was the mechanism of action of ω-3 fatty acids.
If ω-3 fatty acids are competitive with ATP, then higher ATP concentrations should cause a shift to a higher IC 50 for ω-3 fatty acid inhibition of PKA. We therefore compared the IC 50 for EPA inhibition of PKA, using two different final ATP concentrations: 100 µM and 500 µM. EPA reduced PKA activity indistinguishably under both concentrations with no significant difference Figure   3 ). These data strongly suggest that EPA is not a competitive inhibitor of ATP binding to PKA.
Omega3 fatty acid inhibition of PKC, CaMKII and MAPK.
If fatty acids unsaturated in the ω-3 position have the capability of inhibiting the catalytic subunit of PKA, then it is reasonable to hypothesize that this effect may transcend to other protein kinases with homologous catalytic domains. Therefore we examined the effect of different longchain fatty acids on two other kinases; PKC and CaMKII. We tested EPA, DHA and AA on PKC catalytic domain phosphotransferase activity using a peptide substrate (in vitro) using increasing fatty acid concentrations ( Figure 4A ). We found that ω-3 fatty acids inhibited PKC and, similar to results for PKA, EPA was found to be a more potent inhibitor of PKC activity than DHA (IC 50 for EPA = 2 µM compared to 36 µM for DHA). AA, which lacks the ω-3 double bond, was used as a control and did not cause significant inhibition of PKC enzymatic activity (IC 50 >400 µM).
Similarly, the inhibitory effect of EPA and DHA was also shown in assays using the catalytic subunit of CaMKII ( Figure 4B ). Both EPA and DHA inhibited CaMKII activity at relatively low concentrations with a calculated IC 50 for EPA of 15 µM and for DHA of 36 µM. Thus similar to what was observed with PKC and PKA, EPA and DHA inhibit CaMKII.
The second messenger-regulated kinases PKA, PKC and CaMKII share sequence homology within their catalytic domains The ERK MAPKs are regulated by phosphorylation and not second-messengers, but nevertheless exhibit structural homology to the PKA, PKC and CaMKII catalytic domains (22, 23) . We therefore determined if ω-3 fatty acids inhibited MAPK activity.
To determine the potency of EPA and DHA at inhibiting MAPK activity, increasing concentrations of both fatty acids (0.1 µM to 100 µM) were used ( Figure 4C ). Both ω-3 fatty acids inhibited MAPK activity, and EPA was a slightly more potent inhibitor of MAPK activity than DHA (IC 50 for EPA = 23 µM and for DHA = 34 µM). Overall these data show that DHA and EPA act as broad-spectrum kinase inhibitors, blocking not only the activity of PKA, PKC, and CaMKII, but also the activity of MAPK. VPA and 2-ene VPA exhibit no effect on PKC or PKA.
Valproic acid (VPA, 2-propylpentanoic acid), is short chain-length, eight carbon, branched fatty acid ( Figure 1 ) and, like ω-3 fatty acids, VPA has recently been used for treatment of Bipolar Disorder (24,25). 2-ene VPA (2-ene valproate, 2 propyl-2-pentenoic acid) (Figure 1) is the major VPA metabolite in humans, which also contains the ω-3 moiety. Given that VPA and the ω-3 fatty acids DHA and EPA exhibit similar neurologic effects, we thought it an intriguing possibility that 2-ene VPA might inhibit protein kinases in a fashion similar to the long-chain fatty acids described above. Therefore we tested whether VPA or 2-ene VPA had the same inhibitory effect as long-chain ω-3 fatty acids on PKA and PKC activity in vitro. As expected, we found a lack of an inhibitory effect of VPA on PKC or PKA phosphotransferase activity at concentrations ranging from 1 to 200 µM (data not shown). Interestingly, there was also a lack of inhibition on PKA and PKC activity with 2-ene VPA using concentrations of 100, 200 and 400 µM ( Figure 5) . Thus, the ω-3 moiety within the 2-ene VPA does not confer significant inhibitory efficacy for PKC or PKA activity in vitro. This lack of effect of 2-ene VPA may be due to its overall short chain-length or the proximity of the carboxylic acid in relation to the ω-3 double bond. These data also indicate that neither VPA nor its major metabolite act by directly inhibiting PKA or PKC, suggesting that a different mechanism of action exists in vivo for VPA versus ω-3 long-chain fatty acids.
DHA and EPA can inhibit serotonin-induced activation of MAPK.
While the results thus far demonstrate that DHA and EPA have effects on kinase activity in vitro, they do not address whether the compounds are capable of inhibiting protein kinases in the intact cell. For the next stage of our studies we sought to develop a preparation that we could use to test the efficacy of ω-3 fatty acids in inhibiting protein kinases in living cells. The serotonergic signal transduction pathway can activate MAPK in a PKA-dependent process in aplysia sensory neurons, but the effects of 5-HT on MAPK in the mammalian brain have not been determined (26) . We reasoned that investigating serotonin-coupled kinase activation was a desirable avenue of pursuit because the serotonergic system is widely implicated in affective disorders for which ω-3 fatty acids have beneficial effects. In our first studies, we found that 10 µM 5-HT caused MAPK activation in hippocampal slices evaluated by the increased phosphorylation of p42 MAPK ( Figure 6 ). The control compounds behenic acid and arachidic acid showed no inhibition 
Discussion
The purpose of these studies was to investigate the mechanism of action of ω-3 fatty acids and to clarify the effects of ω-3 fatty acids on specific protein kinases established as playing important roles in signal transduction, synaptic function and plasticity in the mammalian CNS. In our in vitro experiments, EPA and DHA significantly reduced the activity of PKA, PKC, MAPK and CaMKII. This effect was in contrast to control fatty acids of similar composition that were saturated at the ω-3 carbon (BA, DTEA, AA, arachidic acid), which exhibited a greatly diminished potency in kinase inhibition. Our in vitro observations that ω-3 fatty acids may act as non-specific protein kinase inhibitors is an important first-step in understanding the potential molecular targets of free ω-3 fatty acids in the cell. To test our hypothesis that ω-3 fatty acid effects on protein kinases can have a physiologic effect in living tissue, we evaluated DHA and EPA effects on mouse hippocampal slices. We found that application of low concentrations of ω-3 fatty acids blocked 5-HT-receptor induced kinase activation and blocked the induction of LTP in area CA1 of the hippocampus. This indicates that ω-3 fatty acids block protein kinase activity in the intact cell as well as in vitro, and suggests the interesting possibility that neuronal kinase inhibition may underlie the known therapeutic effects of ω-3 fatty acids in affective disorders.
In our experiments, we measured the phosphotransferase activity of PKA, PKC, MAPK and CaMKII in the presence of the ω-3 fatty acids DHA and EPA and fatty acids of equal length with different degrees and sites of saturation. Both DHA and EPA appear to reduce kinase activity at low concentrations in vitro with EPA appearing to be slightly more efficient in reducing kinase activity than DHA. Importantly, only the catalytic domains of PKA, PKC and CaMKII were used in these assays. Thus in our experiments ω-3 fatty acid interactions occur at site(s) other than the second messenger binding sites present in the holoenzymes. However, the observed effect of ω-3 fatty acids did not appear to be due to competitive inhibition at the ATP binding domain, as increasing the concentration of ATP in the kinase assay had no effect on the efficacy of EPA inhibition. Recently, Radominska-Pandya, et al. (28) reported that direct binding of alltrans-retinoic acid (atRA) to PKC can significantly reduce its activity in vitro, however the enzyme region responsible for this interaction has yet to be identified. Given that atRA is also a by guest on http://www.jbc.org/
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Protein Kinase inhibition by Omega-3 Fatty Acids 14 long-chain, unbranched fatty acid, it is an appealing speculation that atRA and ω-3 fatty acids share a similar locus of action.
We show that addition of 5-HT (10 µM) to hippocampal slices can activate MAPK. This activation can be blocked by ω-3 fatty acids, but not with structurally similar fatty acids lacking the ω-3 double bond moiety. Our results showing the effect of ω-3 fatty acids on 5-HTdependent signal transduction raises the interesting idea that this pathway may be a locus for the mood-stabilizing effects of ω-3 fatty acids. This hypothesis is supported by observations that alterations in serotonergic neurotransmission have been implicated in the pathophysiology of major depression and suicide. Moreover, treatment of depression often involves the regulation of 5-HT-coupled intracellular signal transduction pathways through the therapeutic action of 5-HT specific reuptake inhibitors, which act to desensitize 5-HT receptors and depress serotonergic processes. A normal function for ω-3 fatty acids in serotonergic function may exist, in light of studies showing that chronic ω-3 fatty acid deficiency in rats can alter serotonergic neurotransmission (3), although it is unknown if these effects are due to changes in membraneassociated ω-3 fatty acids or the availability of free ω-3 fatty acids. Overall, our results support the hypothesis that a means by which ω-3 fatty acids may exert their beneficial mood stabilizing actions is through the suppression of 5-HT-dependent signal transduction pathways.
We determined that perfusion of ω-3 fatty acids prevents the induction of LTP in area CA1 of the hippocampus. The necessity for PKA, PKC, MAPK and CaMKII in synaptic plasticity is well established, as numerous studies have shown that inhibition of one or more of these kinases, or pathways in which these kinases are involved, will disrupt LTP induction (19, (29) (30) (31) .
Perfusion of hippocampal slices with low concentrations (10 µM) DHA or EPA, but not arachidonic acid, was sufficient to disrupt induction of LTP. This strongly suggests that the inhibition of CA1 LTP is the result of DHA and EPA-dependent reductions in the activities of several kinases involved in LTP induction. These results may give a glimpse into the ability of ω-3 fatty acids to exert an effect on neuronal function in vivo. The ω-3 fatty acid concentrations we used in our LTP studies caused only a modest kinase inhibition in our in vitro studies, but were nonetheless able to block LTP induction. It is possible that in these experiments hippocampal slices are concentrating the highly hydrophobic fatty acids, increasing the concentration locally. An interesting alternative possibility is that the effect is due to the kinasedependent signal integration and amplification that occurs during high frequency stimulusinduced LTP induction. In this scenario, slight reductions in the activity of CaMKII, PKA, PKC and MAPK sum up to prevent the cell from reaching an LTP induction threshold. Regardless, reducing kinase activity through ω-3 fatty acid application does not appear to interrupt basic synaptic function since the application of EPA or DHA appears to have no effect on normal CA1 synaptic transmission.
The present studies complement previous research into the action of dietary ω-3 fatty acids, specifically on membrane composition, and the associated changes in synaptic function. Work by (32), modulation of calcium signaling in vascular smooth muscle (33) and in proper retinal function (34, 35) . In addition, it has long been known that release of ω-3 fatty acids can occur following electroconvulsive shock and ischemia (36, 37) and, more recently, the identification of specific sites for ω-3 fatty acid accumulation at the synapse (38,39) would appear to support the hypothesis that both free and membrane bound ω-3 fatty acids may play diverse roles in synaptic function.
While we have focused our studies on direct effects of ω-3 fatty acids on protein kinases, it is possible, even likely, that ω-3 fatty acids play multiple roles in neuronal function and regulation through direct action upon membrane-bound proteins, alterations in physical membrane characteristics, and direct action upon protein kinases. However, we find it interesting to consider the possible role for direct ω-3 fatty acid-induced inhibition of protein kinases in the In conclusion, our results illustrate that one mechanism by which ω-3 fatty acids can affect cellular function is to reduce the activity of several protein kinases and thereby down-regulate the signal transduction pathways in which these kinases are involved. This potential mechanism should be kept in mind when considering the therapeutic benefits of ω-3 fatty acids in heart disease, inflammation, metabolic disorders, cancer, and neuropsychiatric disorders. were probed for phospho-MAPK (p42) and standardized to non-treated controls. Application of ω-3 fatty acids (DHA and EPA) or control fatty acids (behenic acid and arachidic acid) to hippocampal slices alone had no effect on basal MAPK activation (data not shown). Columns and error bars represent the mean±SEM from n=3 or 5 western blot analyses (**=p<0.01). 
